Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has issued an update.
Hansoh Pharmaceutical Group Company Limited announced that its product, Hengmeida (Ibrexafungerp Tablets), has received drug registration approval from the National Medical Products Administration of China. This approval allows the company to market the drug for the treatment of vulvovaginal candidiasis in adult and post-menarche adolescent women, potentially enhancing its market position and expanding its product offerings in the pharmaceutical industry.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and production of drugs. The company operates in the healthcare industry, providing pharmaceutical products to treat various medical conditions.
YTD Price Performance: 40.34%
Average Trading Volume: 10,359,841
Technical Sentiment Signal: Sell
Current Market Cap: HK$144.2B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.